Cancer therapy developer Lava Therapeutics has raised $18.6m in a round featuring Merck Research Laboratories unit MRL Ventures.
Netherlands-based immuno-oncology treatment developer Lava Therapeutics has raised €16m ($18.6m) in funding from investors including MRL Ventures Fund, a subsidiary of pharmaceutical firm Merck & Co’s Merck Research Laboratories division.
Gilde Healthcare and Versant Ventures co-led the round, which also featured Lava’s founder investors, fellow investment firms Lupus Ventures and Biox Biosciences. Lava described the round as its first major institutional financing.
Founded in 2016, Lava is working on cancer treatments based on developing bispecific antibodies intended to activate certain…
